MX2011011273A - Derivados de isoxazol-pirazol. - Google Patents
Derivados de isoxazol-pirazol.Info
- Publication number
- MX2011011273A MX2011011273A MX2011011273A MX2011011273A MX2011011273A MX 2011011273 A MX2011011273 A MX 2011011273A MX 2011011273 A MX2011011273 A MX 2011011273A MX 2011011273 A MX2011011273 A MX 2011011273A MX 2011011273 A MX2011011273 A MX 2011011273A
- Authority
- MX
- Mexico
- Prior art keywords
- isoxazole
- pyrazole derivatives
- present
- cognitive
- gaba
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Neurology (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Physical Education & Sports Medicine (AREA)
- Psychology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Anesthesiology (AREA)
- Addiction (AREA)
- Hospice & Palliative Care (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
La presente invención se refiere a derivados de isoxazol-pirazol de la fórmula I (ver fórmula (I)) que tienen afinidad y selectividad para el receptor a5 de GABA A, a su elaboración, a composiciones farmacéuticas que los contienen y a su uso como medicamentos. Los compuestos activos de la presente invención son útiles como potenciadores cognitivos o para el tratamiento terapéutico y/o profiláctico de trastornos cognitivos tales como enfermedad de Alzheimer.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP09159364 | 2009-05-05 | ||
PCT/EP2010/055694 WO2010127975A1 (en) | 2009-05-05 | 2010-04-28 | Isoxazole-pyrazole derivatives |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2011011273A true MX2011011273A (es) | 2011-11-04 |
Family
ID=42470655
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2011011273A MX2011011273A (es) | 2009-05-05 | 2010-04-28 | Derivados de isoxazol-pirazol. |
Country Status (12)
Country | Link |
---|---|
US (1) | US8163728B2 (es) |
EP (1) | EP2427455B1 (es) |
JP (1) | JP5460858B2 (es) |
KR (1) | KR101384829B1 (es) |
CN (1) | CN102414205B (es) |
AU (1) | AU2010244552A1 (es) |
BR (1) | BRPI1014454A2 (es) |
CA (1) | CA2760746C (es) |
IL (1) | IL214941A0 (es) |
MX (1) | MX2011011273A (es) |
SG (1) | SG175333A1 (es) |
WO (1) | WO2010127975A1 (es) |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TW201033201A (en) * | 2009-02-19 | 2010-09-16 | Hoffmann La Roche | Isoxazole-isoxazole and isoxazole-isothiazole derivatives |
CA2815741A1 (en) * | 2010-11-09 | 2012-05-18 | F. Hoffmann-La Roche Ag | Triazole derivatives as ligands for gaba receptors |
AU2012320581B2 (en) | 2011-10-06 | 2017-03-30 | Bayer Intellectual Property Gmbh | Heterocyclylpyri (mi) dinylpyrazole as fungicidals |
US20150374705A1 (en) | 2012-02-14 | 2015-12-31 | Shanghai Institues for Biological Sciences | Substances for treatment or relief of pain |
WO2014001279A1 (en) | 2012-06-26 | 2014-01-03 | Aniona Aps | A phenyl triazole derivative and its use for modulating the gabaa receptor complex |
AU2013283488A1 (en) | 2012-06-26 | 2015-01-15 | Saniona Aps | A phenyl triazole derivative and its use for modulating the GABAA receptor complex |
WO2014001280A1 (en) | 2012-06-26 | 2014-01-03 | Aniona Aps | A phenyl triazole derivative and its use for modulating the gabaa receptor complex |
WO2014001278A1 (en) | 2012-06-26 | 2014-01-03 | Aniona Aps | A phenyl triazole derivative and its use for modulating the gabaa receptor complex |
JP6224097B2 (ja) | 2012-06-26 | 2017-11-01 | サニオナ・エイピイエス | フェニルトリアゾール誘導体及びgabaa受受容体複合体を調節するための該フェニルトリアゾール誘導体の使用 |
CA3079833A1 (en) | 2017-11-01 | 2019-05-09 | Bristol-Myers Squibb Company | Bridged bicyclic compounds as farnesoid x receptor modulators |
KR20210021019A (ko) * | 2018-06-13 | 2021-02-24 | 에프. 호프만-라 로슈 아게 | GABA A α5 PAM으로서의 이속사졸릴 에테르 유도체 |
BR102019014802A2 (pt) | 2018-07-20 | 2020-02-04 | Boehringer Ingelheim Int | difluorometil-fenil triazóis |
HU231223B1 (hu) | 2018-09-28 | 2022-01-28 | Richter Gedeon Nyrt. | GABAA A5 receptor modulátor hatású biciklusos vegyületek |
CN111533682B (zh) * | 2020-05-29 | 2022-03-01 | 清华大学 | 帕罗西汀及其类似物的制备方法 |
Family Cites Families (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3525205A1 (de) | 1984-09-11 | 1986-03-20 | Hoechst Ag, 6230 Frankfurt | Pflanzenschuetzende mittel auf basis von 1,2,4-triazolderivaten sowie neue derivate des 1,2,4-triazols |
GB9808663D0 (en) | 1998-04-23 | 1998-06-24 | Merck Sharp & Dohme | Therapeutic agents |
US6660753B2 (en) | 1999-08-19 | 2003-12-09 | Nps Pharmaceuticals, Inc. | Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists |
IT1314191B1 (it) | 1999-10-18 | 2002-12-06 | Recordati Chem Pharm | Derivati isossazolcarbossamidici |
MXPA02004735A (es) | 1999-11-12 | 2003-01-28 | Orive Javier Uhthoff | Compuestos heteroaromaticos, biciclicos y triciclicos. |
PA8535601A1 (es) | 2000-12-21 | 2002-11-28 | Pfizer | Derivados benzimidazol y piridilimidazol como ligandos para gabaa |
GB0108475D0 (en) | 2001-04-04 | 2001-05-23 | Merck Sharp & Dohme | New compounds |
CN1671386A (zh) | 2001-07-05 | 2005-09-21 | H·隆德贝克有限公司 | 作为mch选择性拮抗剂的取代苯胺基哌啶 |
ATE381542T1 (de) | 2001-08-13 | 2008-01-15 | Phenex Pharmaceuticals Ag | Nr1h4-kern-rezeptor-bindende verbindungen |
AU2002353844A1 (en) | 2001-11-20 | 2003-06-10 | Eli Lilly And Company | Beta 3 adrenergic agonists |
GB0128160D0 (en) | 2001-11-23 | 2002-01-16 | Merck Sharp & Dohme | Novel compounds |
AU2003290700A1 (en) | 2002-11-22 | 2004-06-18 | Smithkline Beecham Corporation | Farnesoid x receptor agonists |
GB0318447D0 (en) | 2003-08-05 | 2003-09-10 | Merck Sharp & Dohme | Therapeutic agents |
EP1756086B1 (en) | 2004-06-01 | 2008-06-04 | F.Hoffmann-La Roche Ag | Pyridin-4-yl-ethynyl-imidazoles and pyrazoles as mglu5 receptor antagonists |
US20080153869A1 (en) | 2004-06-14 | 2008-06-26 | Bressi Jerome C | Kinase Inhibitors |
JP4620123B2 (ja) | 2004-10-01 | 2011-01-26 | エフ.ホフマン−ラ ロシュ アーゲー | ヘキサフルオロイソプロパノール置換エーテル誘導体 |
EP1812427A4 (en) | 2004-10-15 | 2009-10-14 | Scripps Research Inst | FATTY ACID AMIDE HYDROLASE OXADIAZOLE KETONE INHIBITORS |
US20070060589A1 (en) | 2004-12-21 | 2007-03-15 | Purandare Ashok V | Inhibitors of protein arginine methyl transferases |
ATE484416T1 (de) | 2005-07-20 | 2010-10-15 | Prospective Concepts Ag | Pneumatisch verstellbare seitenwangen für fahrzeugsitze |
BRPI0616184A2 (pt) * | 2005-09-19 | 2011-06-07 | Hoffmann La Roche | derivados de isoxazolo como agonistas inversos gaba a alfa 5, processo para a preparação dos mesmos, medicamento e uso dos referidos derivados |
WO2007052843A1 (ja) | 2005-11-04 | 2007-05-10 | Takeda Pharmaceutical Company Limited | 複素環アミド化合物およびその用途 |
JP5081161B2 (ja) | 2005-12-19 | 2012-11-21 | スミスクライン ビーチャム コーポレーション | ファルネソイドx受容体アゴニスト |
ES2452031T3 (es) | 2006-02-03 | 2014-03-31 | Eli Lilly & Company | Compuestos y procedimientos para modular receptores FX |
JP2007230909A (ja) | 2006-03-01 | 2007-09-13 | Univ Of Tokyo | 置換イソキサゾール誘導体 |
JP5087616B2 (ja) * | 2006-05-31 | 2012-12-05 | エフ.ホフマン−ラ ロシュ アーゲー | アリール−4−エチニル−イソオキサゾール誘導体 |
EP1894924A1 (en) | 2006-08-29 | 2008-03-05 | Phenex Pharmaceuticals AG | Heterocyclic FXR binding compounds |
EP1894928A1 (en) | 2006-08-29 | 2008-03-05 | PheneX Pharmaceuticals AG | Heterocyclic fxr binding compounds |
US7943653B2 (en) * | 2007-08-13 | 2011-05-17 | Janssen Pharmaceutica N.V. | Substituted 5-vinylphenyl-1-phenyl-pyrazole cannabinoid modulators |
US7943619B2 (en) * | 2007-12-04 | 2011-05-17 | Hoffmann-La Roche Inc. | Isoxazolo-pyridazine derivatives |
KR20120102117A (ko) * | 2007-12-04 | 2012-09-17 | 에프. 호프만-라 로슈 아게 | 아이속사졸로-피리딘 유도체 |
MX2010005753A (es) * | 2007-12-04 | 2010-06-15 | Hoffmann La Roche | Derivados de isoxazolo-pirazina. |
-
2010
- 2010-04-28 EP EP10715270.4A patent/EP2427455B1/en active Active
- 2010-04-28 US US12/768,770 patent/US8163728B2/en active Active
- 2010-04-28 CA CA2760746A patent/CA2760746C/en not_active Expired - Fee Related
- 2010-04-28 CN CN201080019763.0A patent/CN102414205B/zh not_active Expired - Fee Related
- 2010-04-28 JP JP2012508991A patent/JP5460858B2/ja active Active
- 2010-04-28 WO PCT/EP2010/055694 patent/WO2010127975A1/en active Application Filing
- 2010-04-28 AU AU2010244552A patent/AU2010244552A1/en not_active Abandoned
- 2010-04-28 KR KR1020117028881A patent/KR101384829B1/ko not_active IP Right Cessation
- 2010-04-28 SG SG2011077906A patent/SG175333A1/en unknown
- 2010-04-28 BR BRPI1014454A patent/BRPI1014454A2/pt not_active IP Right Cessation
- 2010-04-28 MX MX2011011273A patent/MX2011011273A/es active IP Right Grant
-
2011
- 2011-09-01 IL IL214941A patent/IL214941A0/en unknown
Also Published As
Publication number | Publication date |
---|---|
IL214941A0 (en) | 2011-11-30 |
SG175333A1 (en) | 2011-12-29 |
WO2010127975A1 (en) | 2010-11-11 |
JP5460858B2 (ja) | 2014-04-02 |
KR20120132614A (ko) | 2012-12-06 |
CA2760746A1 (en) | 2010-11-11 |
EP2427455A1 (en) | 2012-03-14 |
AU2010244552A1 (en) | 2011-09-29 |
US20100286115A1 (en) | 2010-11-11 |
JP2012526070A (ja) | 2012-10-25 |
EP2427455B1 (en) | 2020-01-15 |
CN102414205B (zh) | 2014-11-05 |
BRPI1014454A2 (pt) | 2016-04-05 |
US8163728B2 (en) | 2012-04-24 |
CA2760746C (en) | 2017-07-11 |
KR101384829B1 (ko) | 2014-04-15 |
CN102414205A (zh) | 2012-04-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2011011489A (es) | Derivados de isoxazol-piridina. | |
MX2011007774A (es) | Derivados de isoxazol-isoxazol e isoxazol-isotiazol. | |
MX2011011273A (es) | Derivados de isoxazol-pirazol. | |
MX2011011477A (es) | Derivados de isoxazol-piridazina. | |
MX2009014001A (es) | Derivados de isoxazol-imidazol. | |
EA200901373A1 (ru) | Аминогетероциклические соединения | |
TW201144302A (en) | 2,5,6,7-tetrahydro-[1,4]oxazepin-3-ylamine or 2,3,6,7-tetrahydro-[1,4]oxazepin-5-ylamine compounds | |
TN2012000231A1 (en) | Quinoline amide m1 receptor positive allosteric modulators | |
MX2011011490A (es) | Derivados de isoxazol-tiazol como agonistas inversos del receptor de acido gamma-aminobutirico a (gaba a), para usarse en el tratamiento de trastornos cognitivos. | |
IN2012DN00766A (es) | ||
MX2013004588A (es) | Derivados de triazol y su uso para trastornos neurologicos. | |
MX2010004026A (es) | Piperidino-dihidrotienopirimidinas sustituidas. | |
WO2007048801A3 (en) | Sexual desire enhancing medicaments comprising benzimidazolone derivatives | |
DE602007001893D1 (en) | Aryl-4-ethinylisoxazolderivate | |
HK1154587A1 (en) | Aryl methyl benzoquinazolinone m1 receptor positive allosteric modulators | |
MX2010009752A (es) | Compuestos de oxadiazoantraceno para el tratamiento de diabetes. | |
MX2011007772A (es) | Derivados de isoxazol/o-piridina con enlazador etilo y etenilo. | |
EP2582676A4 (en) | POSITIVE ALLOSTERIC TETRAHYDROCHINOLINE AMID M1 RECEPTOR MODULATORS | |
TR201909277T4 (tr) | Rasajilinin genişletilmiş salınım formülasyonları ve kullanım alanları. | |
MX2013008056A (es) | 1,4-oxazepinas como inhibidores de beta-secretasa 1 (bace1) y/o beta-secretasa 2 (bace2). | |
MX2014003408A (es) | N-(3-(2-amino-6,6-difluor-4,4a,5,6,7,7a-hexahidro-ciclopenta-[e][ 1,3]oxazin-4-il)-fenil)-amidas como inhibidores de la beta-secretasa 1 (bace1). | |
MX2012002583A (es) | Moduladores de piranil aril metil benzoquinazolinona alostericos positivos del receptor m1. | |
GEP20166483B (en) | Phenyl-3-aza-bicyclo[3.1.0] hex-3-yl-methanones and the use thereof as medicament | |
MX2011011303A (es) | Derivados de isoxazol. | |
MX362830B (es) | Agente terapeutico o profilactico para enfermedades del tracto biliar. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant or registration |